Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies

Clinical Rheumatology
Claudia FabianiLuca Cantarini

Abstract

The primary aim of the study was to evaluate the efficacy of tumor necrosis factor (TNF)-α blockers adalimumab (ADA) and infliximab (IFX) in refractory sight-threatening retinal vasculitis (RV) during a 12-month follow-up period. Secondary aims were to evaluate (i) any impact of concomitant conventional disease-modifying anti-rheumatic drugs (cDMARDs) and different lines of biologic therapy; (ii) any difference in terms of efficacy between ADA and IFX; (iii) consequences of biotherapies on the best-corrected visual acuity (BCVA); (iv) corticosteroid-sparing effect; and (vi) ocular complications during anti-TNF-α treatment. Demographic, clinical, and therapeutic data were retrospectively collected from the medical records and statistically analyzed. Forty-eight patients (82 eyes) were recruited, 22 (45.8%) of which received IFX and 26 (54.2%) ADA. The percentages of patients achieving RV remission within 3 and 12 months were 54 and 86%, respectively. A significant decrease in RV detection was identified from baseline to 3-month (p < 0.0001) and 12-month (p < 0.0001) assessments and between 3-month and 12-month visits (p = 0.004). No differences were identified in terms of RV resolution between (i) patients undergoing monotherapy...Continue Reading

References

Feb 5, 2008·Annals of the Rheumatic Diseases·G HatemiUNKNOWN EULAR Expert Committee
Oct 22, 2008·American Journal of Ophthalmology·Khalid F Tabbara, Amal I Al-Hemidan
Nov 11, 2008·Scandinavian Journal of Rheumatology·R Lopez-GonzalezE Pato
Apr 25, 2012·Ophthalmology·Manuel Díaz-LlopisJ Fernando Arevalo
Jun 23, 2012·Rheumatology·Daniela PerraGerard Espinosa
Sep 8, 2012·Clinical Rheumatology·Sofia AndroudiShree K Kurup
Feb 11, 2014·The British Journal of Ophthalmology·Amro AliJames T Rosenbaum
May 20, 2014·Journal of Ophthalmology·Lazha TalatOren Tomkins-Netzer
Oct 28, 2014·International Journal of Clinical Pharmacology and Therapeutics·Joaquín Borrás-BlascoLucia Gimeno Mallench
Jul 15, 2015·Journal of Autoimmunity·H ValletUNKNOWN French Behçet Network
Jul 23, 2015·Retina·Pramod K SharmaC Stephen Foster
Mar 6, 2016·Current Opinion in Rheumatology·James T RosenbaumPhoebe Lin
Feb 21, 2018·The British Journal of Ophthalmology·Jonathan Tl LeeLyndell L Lim

❮ Previous
Next ❯

Citations

Mar 20, 2019·Expert Opinion on Biological Therapy·Sara TouhamiDavid Saadoun
Jul 24, 2020·Expert Review of Clinical Immunology·Carla GaggianoClaudia Fabiani
Jul 19, 2019·Internal and Emergency Medicine·Giacomo Emmi, Domenico Prisco
Jun 9, 2020·Mediators of Inflammation·Jurgen SotaClaudia Fabiani
Jan 27, 2019·Internal and Emergency Medicine·Sinem Nihal Esatoglu, Gulen Hatemi
Sep 10, 2019·Expert Opinion on Emerging Drugs·Uwe PleyerJudith Rademacher
Feb 26, 2019·Rheumatology International·Alessandra BettiolGiacomo Emmi
Jan 26, 2021·Expert Review of Clinical Pharmacology·Ogugua Ndili ObiRobert P Baughman
Jan 30, 2021·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Gamze Ucan GunduzSara S Kilic
Nov 12, 2020·Journal of Clinical Medicine·Mathilde LeclercqDavid Saadoun
Dec 19, 2020·Scientific Reports·Noe HoriguchiKyoko Ohno-Matsui
May 26, 2020·Survey of Ophthalmology·Ghazala A Datoo O'Keefe, Narsing Rao
Apr 11, 2021·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Miaoli LinC Stephen Foster
Oct 3, 2020·The Journal of Rheumatology·José Luis Martín-VarillasUNKNOWN Ricardo Blanco on behalf of the Spanish Collaborative Group of Refractory Behçet’s Disease

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.